

Whole Exome Sequencing (WES)

Overview

- Sequences only protein-coding regions (exons)
- Covers ~1-2% of genome (~30-50 Mb)
- Captures ~85% of known disease-causing variants

WES Advantages

- Lower cost than WGS
- Higher coverage per dollar
- Easier data analysis
- Smaller file sizes

WES Limitations

- Misses regulatory variants
- Limited structural variant detection
- Capture bias
- Non-coding regions excluded

Coverage

100-150X

Cost


\$300-500

Diagnostic Yield

25-40%

Preferred for Mendelian disorders and cancer driver mutations

WES Workflow Principles



Exome Coverage Concept



$\sim 20,000 \text{ genes} \times \sim 180,000 \text{ exons} = \sim 30-50 \text{ Mb sequenced}$ (1-2% of 3 Gb genome)

Average coverage: 100-150X means each base is read 100-150 times

Higher coverage = Better variant detection accuracy

Step-by-Step Principles

1. DNA Extraction & Quality Control

- Extract high molecular weight genomic DNA from blood, tissue, or saliva
- Quality assessment: DNA concentration ($>50 \text{ ng}/\mu\text{L}$), purity (A₂₆₀/280 ratio ~ 1.8), and integrity
- Typically requires 1-3 μg of input DNA

2. Library Preparation

- DNA fragmentation: Mechanical shearing (sonication) or enzymatic digestion to 150-200 bp fragments
- End repair: Create blunt ends and add 5' phosphate groups
- A-tailing: Add adenine bases to 3' ends
- Adapter ligation: Attach platform-specific adapters with unique barcodes (for multiplexing)

3. Exome Capture (Enrichment)

- **Key Technology:** Uses biotinylated RNA or DNA probes complementary to exonic sequences
- **Hybridization:** Library fragments hybridize with probes in solution (65°C, 16-24 hours)
- **Capture:** Streptavidin-coated magnetic beads bind biotin-labeled probe-target complexes
- **Washing:** Remove non-target DNA fragments through stringent washing steps
- **Popular kits:** Agilent SureSelect, Illumina Nextera, Twist Bioscience
- Enrichment efficiency: Typically 60-80% on-target rate

4. Next-Generation Sequencing

- **Platform:** Primarily Illumina (NovaSeq, NextSeq) or MGI sequencers
- **Chemistry:** Sequencing by synthesis (SBS) with fluorescent nucleotides
- **Read configuration:** Paired-end sequencing (2 × 150 bp most common)
- **Coverage target:** Mean depth of 100-150X for clinical applications
- **Output:** FASTQ files containing millions of short sequence reads
- Run time: 12-48 hours depending on platform and throughput

5. Bioinformatics Analysis Pipeline

- **Quality control:** FastQC analysis, adapter trimming, quality filtering
- **Alignment:** Map reads to reference genome (hg19/GRCh37 or hg38/GRCh38) using BWA or Bowtie2
- **Post-alignment processing:** Mark duplicates, base quality score recalibration (GATK)
- **Variant calling:** Identify SNVs and indels using GATK HaplotypeCaller, FreeBayes, or similar
- **Annotation:** Functional impact prediction (ANNOVAR, VEP, SnpEff)
- **Filtering:** Remove common variants, prioritize pathogenic mutations
- **Interpretation:** Clinical significance assessment using ACMG guidelines

Technical Considerations

Capture Efficiency Factors

- GC content bias
- Probe design quality
- Hybridization temperature
- DNA input quality
- Target region complexity

Coverage Uniformity

- Not all exons covered equally
- 90-95% of targets at >20X
- Some regions difficult to capture
- GC-rich regions may need higher depth

Limitations to Consider

- Cannot detect balanced translocations
- Misses copy number variants <1 kb
- Poor detection of repeat expansions
- Limited mtDNA analysis

Quality Metrics

- On-target rate: 60-80%
- Mean coverage: 100-150X
- Uniformity: >80% at 20X
- Duplication rate: <20%

Primary Clinical Applications

Rare Diseases

Mendelian disorders, developmental delays

Cancer Genomics

Somatic mutations, driver genes

Carrier Screening

Recessive disease alleles